FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

0 意见· 09/21/23
OncLive® On Air
0

Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.

显示更多

 0 注释 sort   排序方式


下一个